NovaBay Pharmaceuticals Inc

Type: Company
Name: NovaBay Pharmaceuticals Inc
Nationality: United States
Web Address: http://www.novabaypharma.com/
First reported 15 hours ago - Updated 15 hours ago - 1 reports

BioNews [8.21.14]

Top News HeadlineCompanyType Galena Biopharma CEO Allegedly Fired Following Stock-Promotions Scandal, New CEO Named Galena BiopharmaNew CEO J&J, AstraZeneca and Sanofi join Illumina to create a pan-cancer test J&J, AstraZeneca and Sanof ... [Published eClinical Trends - 15 hours ago]
First reported 19 hours ago - Updated 17 hours ago - 2 reports

Stock to Watch: Novabay Pharmaceuticals Down 5.0% (NBY)

Written on Thu, 08/21/2014 - 1:14pmBy Shiri GuptaNovabay Pharmaceuticals ( AMEX:NBY ) is one of today's worst performing penny stocks, down 5.0% to $0.77 on 1.8x average daily volume. Novabay Pharmaceuticals has traded 495,000 shares thus far today, ... [Published Comtex SmarTrend - 17 hours ago]
First reported 23 hours ago - Updated 18 hours ago - 2 reports

NovaBay discontinues studies on NVC-422 for viral conjunctivitis

NovaBay Pharmaceuticals announced in a press release that its phase 2 clinical study for NVC-422 ophthalmic formulation for patients with adenoviral conjunctivitis did not meet primary or secondary endpoints.The endpoints included clearing of bulbar conjunctival ... [Published Orthopedics Today - 18 hours ago]
First reported Aug 20 2014 - Updated Aug 21 2014 - 7 reports

NovaBay shares routed after lead program fails another clinical study

About 9 months after NovaBay Pharmaceuticals ($NBY) reported that its lead anti-infective therapy auriclosene had failed a Phase IIb study for impetigo, the little biotech was forced to come back and concede another setback as an opthalmic solution of ... [Published FierceBiotech - Aug 21 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

BioNews [8.20.14]

Top News HeadlineCompanyType Emergent BioSolutions, MorphoSys AG Strike Prostate Cancer Pact Worth $183 Million Emergent BioSolutions & MorphoSys AGJoint development AstraZeneca's new antibiotic comes through in Phase III AstraZenecaPositive ... [Published eClinical Trends - Aug 20 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 2 reports

Novabay Pharmaceuticals Looks to Continu...

Shares of Novabay Pharmaceuticals (AMEX:NBY) traded at a new 52-week low today of $0.69. This new low was reached on above average trading volume as 3.1 million shares traded hands, while the average 30-day volume is approximately 268,000 shares.Novabay ... [Published Financial News Network online - Aug 20 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

Healthcare Review: Celgene, Emisphere, NovaBay Pharmaceuticals, Amicus Therapeutics, Novartis

U.S. stocks moved higher in early afternoon trading Wednesday as investors prepared for the release of minutes from the Federal Reserve's latest policy meeting.The Dow Jones industrial average was up 46 points, or 0.3 percent, to 16,966 as of 1:30 p.m. ... [Published BioMedReports - Aug 20 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

Mid-Day ETF Update: ETFs Mixed, Stocks Lower on Weak Earnings Reports; FOMC Meeting Minutes Still Ahead

iPath S&P 500 VIX ST Futures ETN ( VXX ): -3.47%Select Financial Sector SPDRs ( XLF ): +0.20%iShares Russell 2000 Index ( IWM ): -0.45%Select Industrial Sector SPDRs ( XLI ): +0.89%Broad Market IndicatorsBroad-market exchange-traded funds, including SPY, ... [Published Nasdaq - Aug 20 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

Morning Market Losers

NovaBay Pharmaceuticals (NYSE: NBY) shares dropped 39.19% to $0.7601 after the company reported that its NVC-422 formulation did not meet primary or secondary endpoints in Phase 2 trial.Real Goods Solar (NASDAQ: RGSE) declined 17.12% to $1.84 after the ... [Published Benzinga.com - Aug 20 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 2 reports

Traders Get Bullish on Shares of Novabay Pharmaceuticals, Shares Up 13.6% (NBY)

Written on Mon, 08/18/2014 - 11:45amBy David DiazNovabay Pharmaceuticals ( AMEX:NBY ) is one of today's best performing low-priced stocks, up 13.6% to $1.17 on 5.5x average daily volume. Novabay Pharmaceuticals has traded 1.1 million shares thus far ... [Published Comtex SmarTrend - Aug 18 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 2 reports

NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2014 Financial Results And A Clinical/Business Update

NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infectives, today reported second quarter 2014 financial results and provided a clinical and commercialization ... [Published BioSpace - Jul 31 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

More on NovaBay Q2 results

10:55 ET | About: NovaBay Pharmaceuticals, Inc. (NBY)NovaBay Pharmaceuticals (NBY +11.7%) Q2 results: Revenue: $21K (+23.5%); Operating Expenses: $3.9M (-21.9%); Operating Loss: ($3.8M) (+8.8%); Net Loss: ($2.9M) (+27.3%); Loss Per Share: ($0.06) (+45.5%); ... [Published Seeking Alpha - Jul 31 2014]

Quotes

...for the company noted that they had enrolled patients around the globe, working at sites in the United States, India, Sri Lanka, and Brazil.  "The endpoints measured clearing of bulbar conjunctival injection (red eye), eradication of adenovirus from the tear film, spread of infection to the fellow eye, reduction in sub-epithelial infiltrates, clearing of blurred vision compared to its Vehicle at Test-of-Cure Visit" the company reported
...Dr. Gauto used a new treatment pioneered by Dr JohnJohn Crew at Seton Hospital in Daly City, California . "Without this treatment Mr. Davila could have had both legs amputated or even lost his life. This is a significant advancement in treatment and I believe we will be able to significantly improve the care of patients suffering from this disease" , said Dr. Gauto
"We recognize Jim's contributions to Neurotrope and are thankful for his management leadership over the past year" stated Messrs. Ramat and Freiman. "We wish him the best in his future endeavors."
"It's extremely important to recognize the disease for what it is, and that there is something available to treat it," he added. "We will send the material anywhere if your doctor will use it."

More Content

All (74) | News (34) | Reports (0) | Blogs (35) | Audio/Video (0) | Fact Sheets (0) | Press Releases (5)
sort by: Date | Relevance
BioNews [8.21.14] [Published eClinical Trends - 15 hours ago]
Stock to Watch: Novabay Pharmaceuticals Down 5.... [Published Comtex SmarTrend - 17 hours ago]
NovaBay discontinues studies on NVC-422 for vir... [Published Orthopedics Today - 18 hours ago]
Stock to Watch: Novabay Pharmaceuticals Down 5.... [Published Individual.com - 19 hours ago]
NovaBay updates results of NVC-422 Phase 2 for ... [Published Individual.com - 23 hours ago]
NovaBay shares routed after lead program fails ... [Published FierceBiotech - Aug 21 2014]
BioNews [8.20.14] [Published eClinical Trends - Aug 20 2014]
Novabay Pharmaceuticals Looks to Continu... [Published Financial News Network online - Aug 20 2014]
Novabay Pharmaceuticals Looks to Continue to Tr... [Published Individual.com - Aug 20 2014]
NovaBay announces results of NVC-422 phase 2 fo... [Published Reuters UK - Aug 20 2014]
NovaBay Pharmaceuticals, Inc. Announces Results... [Published BioSpace - Aug 20 2014]
Healthcare Review: Celgene, Emisphere, NovaBay ... [Published BioMedReports - Aug 20 2014]
Why NovaBay Pharmaceuticals (NBY) Stock Plummet... [Published TheStreet.com - Aug 20 2014]
Mid-Day ETF Update: ETFs Mixed, Stocks Lower on... [Published Nasdaq - Aug 20 2014]
Why NovaBay Pharmaceuticals (NBY) Stock Plummet... [Published The Street Latest - Aug 20 2014]
Rancho Mirage, California Physician Saves Casin... [Published Barchart - Aug 20 2014]
Morning Market Losers [Published Benzinga.com - Aug 20 2014]
NovaBay off big after trial fails [Published Seeking Alpha - Aug 20 2014]
NovaBay Announces Results of NVC-422 Phase 2 fo... [Published Business Wire Health News - Aug 20 2014]
Traders Get Bullish on Shares of Novabay Pharma... [Published Comtex SmarTrend - Aug 18 2014]
Stock to Watch: Novabay Pharmaceuticals Up 13.6... [Published Individual.com - Aug 18 2014]
NovaBay Pharmaceuticals, Inc. Reports Second Qu... [Published BioSpace - Jul 31 2014]
More on NovaBay Q2 results [Published Seeking Alpha - Jul 31 2014]
NovaBay Pharmaceuticals Reports Second Quarter ... [Published Enhanced Online News - Jul 31 2014]
NovaBay Pharmaceuticals Reports Second Quarter ... [Published Business Wire Health News - Jul 31 2014]
Neurotrope : Board of Directors Appoints Chairm... [Published 4 Traders - Jul 31 2014]
In RadioMD Interview, Dr. John Crew Describes S... [Published Noodls - Jul 28 2014]
Doc Touts New Treatment for Flesh-Eating Disease [Published P&T Community - Jul 25 2014]
NovaBay Pharmaceuticals (NBY) Eyelids Cleanser ... [Published Live-PR.com - Jul 25 2014]
NOVABAY PHARMACEUTICALS : Announces Direct US M... [Published 4 Traders - Jul 24 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
BioNews [8.21.14] [Published eClinical Trends - 15 hours ago]
Top News HeadlineCompanyType Galena Biopharma CEO Allegedly Fired Following Stock-Promotions Scandal, New CEO Named Galena BiopharmaNew CEO J&J, AstraZeneca and Sanofi join Illumina to create a pan-cancer test J&J, AstraZeneca and Sanof ...
BioNews [8.20.14] [Published eClinical Trends - Aug 20 2014]
Top News HeadlineCompanyType Emergent BioSolutions, MorphoSys AG Strike Prostate Cancer Pact Worth $183 Million Emergent BioSolutions & MorphoSys AGJoint development AstraZeneca's new antibiotic comes through in Phase III AstraZenecaPositive ...
NovaBay Announces Results of NVC-422 Phase 2 fo... [Published Business Wire Health News - Aug 20 2014]
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY) announced today that its NVC-422 ophthalmic formulation did not meet the primary or secondary endpoints in a Phase 2 clinical study in patients with adenoviral conjunctivitis. ...
NovaBay Pharmaceuticals Reports Second Quarter ... [Published Business Wire Health News - Jul 31 2014]
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infectives, today reported second quarter 2014 financial results ...
NovaBay Pharmaceuticals Announces Direct US Mar... [Published EON Communications - Jul 16 2014]
EMERYVILLE, Calif.--(EON: Enhanced Online News)--NovaBay Pharmaceuticals Announces Direct US Marketing-Sales Campaign For New i-Lid Cleanser Product ...
1 2 3 4 5 6 7

Press Releases

sort by: Date | Relevance
NovaBay Pharmaceuticals, Inc. Announces Pricing... [Published GlobeNewswire: Advertising News - Mar 20 2014]
NovaBay Pharmaceuticals, Inc. Announces Propose... [Published GlobeNewswire: Acquisitions News - Mar 19 2014]
NovaBay Pharmaceuticals Reports Fourth Quarter ... [Published GlobeNewswire: Acquisitions News - Mar 07 2014]
NovaBay CEO Comments on President Obama's 'Supe... [Published GlobeNewswire: Acquisitions News - Mar 06 2014]
NovaBay Pharmaceuticals Grants Principle Busine... [Published GlobeNewswire: Acquisitions News - Feb 26 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.